RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
SoliPharma, a Hangzhou company, completed a $36.5 million financing to support its development of high-end, difficult-to-make generic drugs. The company, founded in 2010, develops products with partners, and registers them in China and the US, with an eye toward global markets over time. Its expertise ranges from early API development, through product development and into regulatory approval. The company’s SoliTech® Solutions division has been given the mission of “bringing challenging molecules to global markets” more quickly. Source: China Biotoday
